Oramed Pharmaceuticals Inc.
ORMPNASDAQHealthcare● Active
$3.64
$-0.07(-1.89%)
Market Cap$148970935
P/E Ratio—
52W High$5.01
52W Low$1.98
Oramed Pharmaceuticals Inc. (ORMP) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ORMP · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-08 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $2.00M | $0.00M | $1.34M | $2.70M | $2.70M |
| Cost of Revenue | $1.99M | $0.19M | $0.00M | $0.00M | $0.00M |
| Gross Profit | $0.01M | ($0.19M) | $1.34M | $2.70M | $2.70M |
| Gross Margin %(computed) | 0.65% | — | 100.00% | 100.00% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $6.38M | $6.32M | $8.97M | $27.64M | $20.99M |
| G&A Expenses | $8.72M | $6.46M | $8.43M | $13.81M | $5.94M |
| Total Operating Expenses | $15.10M | $12.78M | $17.11M | $43.30M | $26.93M |
| Operating Income | ($15.09M) | ($12.78M) | ($15.77M) | ($40.60M) | ($24.22M) |
| Operating Margin %(computed) | -754.40% | — | — | — | -896.15% |
| Interest Income | $2.37M | $0.00M | $8.03M | $3.57M | $0.35M |
| Interest Expense | $0.00M | $0.85M | $3.58M | $0.00M | $0.01M |
| Income Before Tax | $75.32M | ($15.92M) | $5.09M | ($37.66M) | ($22.99M) |
| Income Tax Expense | $11.31M | $3.18M | $0.00M | $0.10M | ($2.88M) |
| Net Income | $64.05M | ($19.10M) | $5.53M | ($37.76M) | ($22.24M) |
| Net Margin %(computed) | — | — | 412.31% | — | -822.72% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $1.53 | $-0.47 | $0.14 | $-0.97 | $-0.78 |
| Wtd Avg Shares | 41.40M | 40.83M | 40.32M | 39.00M | 28.47M |
| EBITDA | $75.44M | ($14.87M) | $7.32M | ($36.98M) | ($25.04M) |
| EBITDA Margin %(computed) | — | — | 546.34% | — | -926.34% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Oramed Pharmaceuticals Inc. data
About Oramed Pharmaceuticals Inc. (ORMP) Income Statement
Oramed Pharmaceuticals Inc. (ORMP) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, ORMP reported revenue of $0.00B, gross profit of $0.00B (gross margin 0.65%), and net income of $0.06B — a net profit margin of 3202.50%.
Frequently asked questions
ORMP · 4 questionsOramed Pharmaceuticals Inc. (ORMP) reported revenue of $0.00B for 2025, up —% year-over-year.
ORMP revenueORMP salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09